Monopar Therapeutics (MNPR) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing treatments for Wilson disease and radiopharmaceuticals for oncology, including late-stage and Phase 1 product candidates targeting advanced cancers expressing uPAR.

• Pipeline built through both in-house development and licensing of late preclinical- and clinical-stage therapeutics.

• Operates as a smaller reporting company, utilizing scaled disclosure and compliance exemptions.

Risk factors and disclosures

• Risks include ability to raise sufficient funds for clinical, regulatory, and commercial development, and to make milestone payments.

• Uncertainties in clinical trial timelines, regulatory reviews, and commercialization challenges.

• Exposure to market, geopolitical, and macroeconomic risks, including inflation, global conflicts, and potential pandemics.

• Reliance on supply chains for radioisotopes and fulfillment logistics for radiopharmaceuticals.

• Incorporated risk disclosures from recent 10-K and 10-Q filings by reference.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, with specific uses detailed in future prospectus supplements.

• Proceeds may be temporarily invested prior to use.